NPY基因启动子多态性与缺血性脑卒中的相关性研究
|
摘要
目的探讨神经肽Y (NPY)基因启动子多态性与缺血性脑卒中的相关性。
方法采用聚合酶链反应(PCR)及基因测序技术,检测450例确诊的缺血性脑卒中患者及423例性别、年龄与之相匹配的正常对照者的NPY基因启动子-399T/C和-883TGins/del两个功能性多态位点的等位基因型、基因型和单倍体型多态性的分布特征情况,Logistic回归分析去除混杂因素影响,以探讨NPY基因启动子基因多态性与缺血性脑卒中的关系。
结果病例组NPY基因启动子-399CC基因型(OR：1.699,95%CI：1.124-2.567,P=0.C11)和-399C等位基因(OR：1.254，95%CI：1.G31-1.524,P=0.023)频率均较正常对照组高,特别是在小动脉闭塞性卒中(SVD)类型中。多因素Logistic回归分析后该结论仍然成立。研究分析发现-883ins/-399C单体型可致罹患缺血性脑卒中的风险增加(P=0.008)。
结论NPY基因启动子-399T/C多态性可能与缺血性脑卒中的发病存在相关,具有-399C等位基因的个体发生缺血性脑卒中的风险可能显著增加。NPY可能在缺血性脑卒中的发病病程中起重要作用。
Objective:To define whether there is a relationship between neuropeptide Y (NPY) gene polymorphism and ischemic stroke in a Chinese Han population.
Methods:We investigated 450 ischemic stroke patients and 423 healthy controls matched for sex and age in a Han Chinese population. Two functional polymorphisms (-883TGins/del and -399 T/C) located in NPY gene promoter were genotyped using polymerase chain reaction and DNA sequencing methods. Multivariate logistic regression analysis was used to remove confounding variables.
Result:Of 2 NPY polymorphisms investigated in our study, the -399CC genotype (OR: 1.699,95% CI:1.124-2.567, P=0.011) and the -399C allele (OR:1.254,95% CI: 1.031-1.524, P=0.023) were more frequent among ischemic stroke patients than in controls, especially in the small vessel disease (SVD) subtype patients. The similar results were observed in multivariable logistic regression analysis. Haplotype analysis revealed that the -883ins/-399C haplotype was a risk marker for ischemic stroke (P=0.008).
Conclusions:The C allele of -399 T/C polymorphism in the promoter regions of NPY is an independent risk factor for ischemic stroke, suggesting that NYP system may involve in the mechanisms of stroke pathology.
方法采用聚合酶链反应(PCR)及基因测序技术,检测450例确诊的缺血性脑卒中患者及423例性别、年龄与之相匹配的正常对照者的NPY基因启动子-399T/C和-883TGins/del两个功能性多态位点的等位基因型、基因型和单倍体型多态性的分布特征情况,Logistic回归分析去除混杂因素影响,以探讨NPY基因启动子基因多态性与缺血性脑卒中的关系。
结果病例组NPY基因启动子-399CC基因型(OR：1.699,95%CI：1.124-2.567,P=0.C11)和-399C等位基因(OR：1.254，95%CI：1.G31-1.524,P=0.023)频率均较正常对照组高,特别是在小动脉闭塞性卒中(SVD)类型中。多因素Logistic回归分析后该结论仍然成立。研究分析发现-883ins/-399C单体型可致罹患缺血性脑卒中的风险增加(P=0.008)。
结论NPY基因启动子-399T/C多态性可能与缺血性脑卒中的发病存在相关,具有-399C等位基因的个体发生缺血性脑卒中的风险可能显著增加。NPY可能在缺血性脑卒中的发病病程中起重要作用。
Objective:To define whether there is a relationship between neuropeptide Y (NPY) gene polymorphism and ischemic stroke in a Chinese Han population.
Methods:We investigated 450 ischemic stroke patients and 423 healthy controls matched for sex and age in a Han Chinese population. Two functional polymorphisms (-883TGins/del and -399 T/C) located in NPY gene promoter were genotyped using polymerase chain reaction and DNA sequencing methods. Multivariate logistic regression analysis was used to remove confounding variables.
Result:Of 2 NPY polymorphisms investigated in our study, the -399CC genotype (OR: 1.699,95% CI:1.124-2.567, P=0.011) and the -399C allele (OR:1.254,95% CI: 1.031-1.524, P=0.023) were more frequent among ischemic stroke patients than in controls, especially in the small vessel disease (SVD) subtype patients. The similar results were observed in multivariable logistic regression analysis. Haplotype analysis revealed that the -883ins/-399C haplotype was a risk marker for ischemic stroke (P=0.008).
Conclusions:The C allele of -399 T/C polymorphism in the promoter regions of NPY is an independent risk factor for ischemic stroke, suggesting that NYP system may involve in the mechanisms of stroke pathology.
引文
[1]. Feigin VL. Stroke epidemiology in the developing world [J]. Lancet,2005, 365:2160-2161.
[2]. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke [J]. Stroke,2004,35: 212-227.
[3]. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes:a family history study [J]. Stroke,2003,34:1364-1369.
[4]. Lundberg JM, Terenius L, Hokfelt T, et al. Neuropeptide Y(NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function [J]. Acta Physiol Scand,1982,116:477-480.
[5]. Walker P, Grouzmann E, Burnier M, et al. The role of neuropeptide Y in cardiovascular regulation [J]. Trends Pharmacol Sci,1991,12:111-115.
[6]. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells:cooperation with noradrenaline and ATP [J]. Regul Pept,1994,50:259-265.
[7]. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium [J]. Circ Res, 1998,83:187-195.
[8]. Renner W, Grammer T, Hoffmann MM, et al. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population [J]. J Hypertens,2004,22:2398-2399.
[9]. Niskanen L, Karvonen MK, Valve R, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects [J]. J Clin Endocrinol Metab, 2000,85:2266-2269.
[10]. Michel MC, Rascher W. Neuropeptide Y:a possible role in hypertension? [J] J Hypertens,1995,13:385-395.
[11]. WHO Special Report. Stroke:recommendations on stroke prevention, diagnosis and therapy [J]. Stroke,1989,20:1407-1431.
[12]. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definition for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment [J]. Stroke,1993,24:35-41.
[13]. Excoffier, L., Laval, G., Schneider, S. Arlequin ver.3.0:an integrated software package for population genetics data analysis. Evol. Bioinform.2005.1, 47-50.
[14]. Jamrozik K, Broadhurst RJ, Anderson CS, et al. The role of lifestyle factors in the etiology of stroke. A population-based case-control study in Perth, Western Australia. Stroke 1994.25:51-9.
[15]. Alberts MJ. Genetics of cerebrovascular disease. Stroke.2004.35:342-344.
[16]. Bak S, Gaist D, Sindrup SH, et al. Genetic liability in stroke:a long-term follow-up study of Danish twins. Stroke.2002.33:769-774.
[17]. Jousilahti P, Rastenyte D, Tuomilehto J, et al. Parental history of cardiovascular disease and risk of stroke:a prospective follow-up of 14371 middle-aged men and women in Finland. Stroke.1997.28:1361-1366.
[18]. Woo D, Kaushal R, Kissela B, et al. Association of Phosphodiesterase 4D With Ischemic Stroke A Population-Based Case-Control Study. Stroke.2006.37:371-6.
[19]. Saleheen D, Bukhari S, Haider SR, et al. Association of Phosphodiesterase 4D Gene With Ischemic Stroke in a Pakistani Population. Stroke.2005.36:2270-7.
[20]. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet.2003.35:131-8.
[21]. Worrall BB, Brott TG, Brown RD Jr, et al. IL1RN VNTR Polymorphism in Ischemic Stroke Analysis in 3 Populations. Stroke.2007.38:1189-96.
[22]. Kim Y, Lee C. The Gene Encoding Transforming Growth Factor β 1Confers Risk of Ischemic Stroke and Vascular Dementia. Stroke.2006.37:2843-5.28.
[23]. Stanzione R., Di Angelantonio E., Evangelista A., et al. β 2-adrenergic receptor gene polymorphisms and risk of ischemic stroke. Am. J. Hypertens.2007.20, 657-662.
[24]. Heckbert S. R., Hindorff L. A., Edwards K. L., et al. Beta2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation. 2003.107,2021-2024.
[25]. Frikke-Schmidt R, Nordestgaard BG, Schnohr P, et al. A single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. A case-control and prospective study. Eur Heart J.2004.25: 943-951.
[26]. Howard TD, Giles WH, Xu J, et al. Promoter Polymorphisms in the Nitric Oxide Synthase 3 Gene Are Associated With Ischemic Stroke Susceptibility in Young Black Women. Stroke.2005.36(9):1848-51.
[27]. Hassan A, Gormley K,O'Sullivan M, et al. Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke.2004.35:654-659.34.
[28]. Voetsch B, Benke KS, Panhuysen CI, et al. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol.2004.61:351-356.
[29]. Slowik A, Dziedzic T, Turaj W, et al. A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke.2004.35:1589-1593.
[30]. Alberts MJ, Tournier-Lasserve E. Update on the genetics of stroke and cerebrovascular disease 2004. Stroke.2005.36:179-81.
[31]. Tatemoto K, Carlquist M, Mutt V. Neuropetide Y-a novel brain peptide with structural similarities to petide YY and pancreatic polypeptide. Nature.1982, 296:659-660.
[32]. Marklund U, Bystrom M, Gedda K, et al. Intron-mediated expression of the human neuropeptideY Y1 receptor. [J] Mol Cell Endocrinol.2002,188:85-97.
[33]. Mullins D, Kirby D, Hwa J, et al. Identification of potent and selective neuropeptide Y Y (1) receptor agonists with orexigenic activity in vivo. [J] Mol Pharmacol. 2001,60; 534-540.
[34]. Ishihara A, Kanatani A, Mashiko S, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain an d associated parameters in diet-induced obese mice. [J] PNAS.2006,103(18):7 154-7 158.
[35]. Pittner RA, Moore C X, Bhavsar S P, et al. Efects of PYY[3-36]in rodent models of diabetes and obesity. [J] Obes Relat Metab Disord.2004,28:963-971.
[36]. Ding B. Distribution of the NPY 1128C allele frequency in different populations [J]. J Neural Transm,2003,110:1199-1204.
[37]. Itokawa M, Arai M, Kato S, et al. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans [J]. Neurosci Lett,2003,347:202-204.
[38]. Shah SH, Freedman NJ, Zhang L, et al. Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis [J]. PLoS Genet,2009,5:e 1000318.
[39]. Allen G, Cheung R, Cechetto D. Neurochemical changes following occlusion of the middle cerebral artery in rats [J]. Neuroscience,1995,68:1037-1050.
[40]. Cheung RT, Diab T, Cechetto DF. Time-course of neuropeptide changes in peri-ischemic zone and amygdala following focal ischemia in rats [J]. J Comp Neurol, 1995,360:101-120.
[41]. Kharlamov EA, Kharlamov A, Kelly KM. Changes in neuropeptide Y protein expression following photothrombotic brain infarction and epileptogenesis [J]. Brain Res,2007,1127:151-162.
[42]. Chaeyoung Lee, Minyoung Kong. An Interactive Association of Common Sequence Variants in the Neuropeptide Y Gene With Susceptibility to Ischemic Stroke [J]. Stroke, 2007,38:2663-2669.
[43]. Minth C, Dixon J. Regulation of the human neuropeptide Y gene. Ann N Y Acad Sci.1990.611:99-110.
[44]. Bray MS, Boerwinkle E, Hanis CL. Sequence Variation within the Neuropeptide Y Gene and Obesity in Mexican Americans. Obes Res.2000.8(3):219-26.
[45]. Zill P, Preuss UW, Koller G, et al. Analysis of Single Nucleotide Polymorphisms and Haplotypes in the Neuropeptide Y Gene:No Evidence for Association With Alcoholism in a German Population Sample. Alcohol Clin Exp Res.2008.32(3):430-4.
[46]. Mottagui-Tabar S, Prince JA, Wahlestedt C, et al. A Novel Single Nucleotide Polymorphism of the Neuropeptide Y (NPY) Gene Associated With Alcohol Dependence. Alcohol Clin Exp Res.2005.29.(5):702-7.
[47]Buckland PR, Hoogendoorn B, Guy CA, et al. A high proportion of polymorphisms in the promoters of brain expressed genes influences transcriptional activity [J]. Biochim Biophys Acta,2004,1690:238-249.
[48]Kim NS, Oh SM, Ko MM, et al. Association of the C-399T promoter polymorphism of neuropeptide Y with susceptibility to ischemic stroke [J]. Clin Biochem,2009,42: 1699-1704.
[49]. Zhou Z, Zhu G, Hariri AR, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature.2008.24;452(7190):997-1001.
[1]. Lundberg JM, Terenius L, Hokfelt T, Martling CR, Tatemoto K, Mutt V, Polak J, BloomS, Goldstein M. Neuropeptide Y(NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982 Dec;116 (4):477-80.
[2]. Billington CJ, Briggs JE, Harker S, Grace M, Levine AS. Neuropeptide Y in hypothalamic paraventricular nucleus:a center coordinating energy metabolism. Am J Physiol.1994 Jun;266 (6 Pt 2):R1765-70.
[3]. Moltz JH, McDonald JK. Neuropeptide Y:direct and indirect action on insulin secretion in the rat. Peptides.1985 Nov-Dec;6 (6):1155-9.
[4]. Heilig M, McLeod S, Koob G.K and Britton K.T., Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41 (1992), pp.61-69.
[5]. C. J. Billington, J. E. Briggs, M. Grace and A. S. Levine, Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism, Am J Physiol 260 (1991), pp. R321-R327.
[6]. P.Walker, E. Grouzmann, M. Burnier and B. Waeber, The role of neuropeptide Y in cardiovascular regulation, Trends Pharmacol Sci 12 (1991), pp.111-115.
[7]. D. Erlinge, J. Brunkwall and L. Edvinsson, Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells:cooperation with noradrenaline and ATP, Regul Pept 50 (1994), pp.259-265.
[8]. Z. Zukowska-Grojec, E. Karwatowska-Prokopczuk, W. Rose, J. Rone, S. Movafagh, H. Ji, Y. Yeh, W. T. Chen, H. K. Kleinman, E. Grouzmann and D. S. Grant, Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium, Circ Res 83 (1998), pp.187-195.
[9]. Renner W, Grammer T, Hoffmann MM, Nauck MS, Winkelmann BR, Boehm BO, Marz W. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens.2004;22:2398-2399.
[10]. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm.2003;110:1199-1204.
[11]. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells:cooperation with noradrenaline and ATP. Regul Pept.1994;50:259-265.
[12]. Michel MC, Rascher W. Neuropeptide Y:a possible role in hypertension? J Hypertens.1995; 13:385-395.
[13]. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polak JM. Neuropeptide Y distribution in the rat brain. Science.1983;221:877-879.
[14].Dumont Y, Fournier A, St Pierre S, Quirion R. Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci.1993;13:73-86.
[15]. Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur. J Neurosci.1999;11:1431-1448.
[16]. Tu B, Timofeeva 0, Jiao Y, Nadler JV. Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain 1. J. Neurosci.2005;25:1718-1729.
[17]. Bidmon HJ, Emde B, Kowalski T, Schmitt M, Mayer B, Kato K, Asayama K, Witte OW, Zilles K. Nitric oxide synthase-I containing cortical interneurons co-express antioxidative enzymes and anti-apoptotic Bcl-2 following focal ischemia:evidence for direct and indirect mechanisms towards their resistance to neuropathology. J Chem Neuroanat.2001;22:167-184.
[18]. Kowianski P, Morys JM, Wojcik S, Dziewiatkowski J, Luczynska A, Spodnik E, Timmermans JP, Morys J. Neuropeptide-containing neurons in the endopiriform region of the rat:morphology and colocalization with calcium-binding proteins and nitric oxide synthase. Brain Res.2004; 996:97-110.
[19]. Tatemoto K, Carlquist M, Mutt V. Neuropetide Y-a novel brain peptide with structural similarities to petide YY and pancreatic polypeptide. Nature.1982, 296:659-660.
[20]. Marklund U, Bystrom M, Gedda K, et al. Intron-mediated expression of the human neuropeptideY Y1 receptor. [J] Mol Cell Endocrinol.2002,188:85-97.
[21]. Mullins D, Kirby D, Hwa J, et al. Identification of potent and selective neuropeptide Y Y(1)receptor agonists with orexigenic activity in vivo. [J] Mol Pharmacol. 2001,60; 534-540.
[22]. Ishihara A, Kanatani A, Mashiko S, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain an d associated parameters in diet-induced obese mice. [J] PNAS.2006,103(18):7 154-7 158.
[23]. Pittner RA, Moore C X, Bhavsar S P, et al. Efects of PYY[3-36]in rodent models of diabetes and obesity. [J] Obes Relat Metab Disord.2004,28:963-971.
[24]. Markus HS, Alberts MJ. Update on genetics of stroke and cerebrovascular disease. Stroke.2006; 37:288-290.
[25]. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes:a family history study. Stroke.2003; 34: 1364-1369.
[26]. Kim Y, Lee C. The gene encoding transforming growth factor β1 confers risk of ischemic stroke and vascular dementia. Stroke.2006; 37:2843-2845.
[27]. Dichgans M, Markus HS. Genetic association studies in stroke:methodological issues and proposed standard criteria. Stroke.2005; 36:2027-2031.
[28]. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature.2001; 410:940-944.
[29]. Michel MC, Rascher W. Neuropeptide Y:a possible role in hypertension? J Hypertens.1995; 13:385-395.
[30]. Renner W, Grammer T, Hoffmann MM, Nauck MS, Winkelmann BR, Boehm BO, Marz W. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population.J Hypertens.2004; 22:2398-2399.
[31]. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm.2003; 110:1199-1204.
[32]. Allen GV, Cheung RT, Cechetto DF. Neurochemical changes following occlusion of the middle cerebral artery in rats. Neuroscience.1995;68:1037-1050.
[33]. Cheung RT, Diab T, Cechetto DF. Time-course of neuropeptide changes in peri-ischemic zone and amygdala following focal ischemia in rats. J Comp Neurol. 1995;360:101-120.
[34]. Grimaldi R, Zoli M, Agnati LF, Ferraguti F, Fuxe K, Toffano G, Zini I. Effects of transient forebrain ischemia on peptidergic neurons and astroglial cells:evidence for recovery of peptide immunoreactivities in neocortex and striatum but not hippocampal formation. Exp. Brain Res.1990;82:123-136.
[35]. Kharlamov EA, Kharlamov A, Kelly KM. Changes in neuropeptide Y protein expression following photothrombotic brain infarction and epileptogenesis. Brain Res. 2007 Jan 5;1127 (1):151-62.
[36]. Chaeyoung Lee, PhD Minyoung Kong, MS. An Interactive Association of Common Sequence Variants in the Neuropeptide Y Gene With Susceptibility to Ischemic Stroke. Stroke.2007 Oct;38 (10):2663-9.
[37]. De Quidt ME, Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system:Ⅱ. Immunohistochemical analysis. Neuroscience 1986;18:545-618.
[38]. Woldbye DP, Larsen PJ, Mikkelsen JD, et al. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat Med 1997:3:761-4.
[39]. Dube C, Brunson KL, Eghbal-Ahmadi M, et al. Endogenous neuropeptide Y prevents recurrence of experimental febrile seizures by increasing seizure threshold. J Mol Neurosci 2005:25:275-83.
[40]. Marsh DJ, Baraban SC, Hollopeter G, et al. Role of the Y5 neuropeptide Y receptor in limbic seizures. Proc Natl Acad Sci USA 1999:96:13518-23.
[41]. Erickson JC, Klegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996;381:415-21.
[42]. Baraban SC, Hollopeter G, Erickson JC, Schwartzkroin PA, Palmiter RD. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci. 1997;17:8927-8936.
[43]. Woldbye, DP; Madsen, TM; Larsen, PJ; Mikkelsen, JD; Bolwig, TG. Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Res.1996;737:162-8.
[44]. Hollrigel, GS; Chen, K; Baram, TZ; Soltesz, I. The pro-convulsant actions of corticotropin-releasing hormone in the hippocampus of infant rats. Neuroscience. 1998;84:71-9.
[45]. Tu, B; Timofeeva,O; Jiao, Y; Nadler, JV. Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain. J Neurosci.2005:25:1718-29.
[46]. Vezzani, A; Sperk, G; Colmers, WF. Neuropeptide Y:emerging evidence for a functional role in seizure modulation. Trends Neurosci.1999;22:25-30.
[47]. Kelly KM, Kharlamov A, Hentosz TM, Kharlamova EA, Williamson JM, Bertram EH III, Kapur J, Armstrong DM. Photothrombotic brain infarction results in seizure activity in aging Fischer 344 and Sprague Dawley rats. Epilepsy Res.2001:47:189-203.
[48]. Kharlamov EA, Jukkola PI, Schmitt KL, Kelly KM. Electrobehavioral characteristics of epileptic rats following photothrombotic brain infarction. Epilepsy Res.2003:56:185-203. [49]. Causing CG, Makus KD, Ma Y, Miller FD, Colmers WF. Selective upregulation of T alpha 1 alpha-tubulin and neuropeptide Y mRNAs after intermittent excitatory stimulation in adult rat hippocampus in vivo. J Comp Neurol.1996;367:132-146.
[50]. Gruber B, Greber S, Rupp E, Sperk G. Differential NPY mRNA expression in granule cells and interneurons of the rat dentate gyrus after kainic acid injection. Hippocampus.1994;4:474-482.
[51]. Marksteiner J, Ortler M, Bellmann R, Sperk G. Neuropeptide Y biosynthesis is markedly induced in mossy fibers during temporal lobe epilepsy of the rat. Neurosci. Lett.1990;112:143-148.
[52]. Marksteiner J, Sperk G. Concomitant increase of somatostatin, neuropeptide Y and glutamate decarboxylase in the frontal cortex of rats with decreased seizure threshold. Neuroscience.1988;26:379-385. [PubMed]
[53]. Marksteiner J, Sperk G, Maas D. Differential increases in brain levels of neuropeptide Y and vasoactive intestinal polypeptide after kainic acid-induced seizures in the rat. Naunyn Schmiedebergs Arch. Pharmacol.1989:339:173-177.
[54]. McCarthy JB, Walker M, Pierce J, Camp P, White JD. Biosynthesis and metabolism of native and oxidized neuropeptide Y in the hippocampal mossy fiber system. J Neurochem. 1998;70:1950-1963.
[55]. Tu B, Timofeeva 0, Jiao Y, Nadler JV. Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain 1. J. Neurosci.2005;25:1718-1729.
[56]. Colmers WF, El Bahh B. Neuropeptide Y and Epilepsy. Epilepsy Curr. 2003;3:53-58.
[57]. DePrato Primeaux S, Holmes PV, Martin RJ, Dean RG, Edwards GL. Experimentally induced attenuation of neuropeptide-Y gene expression in transgenic mice increases mortality rate following seizures. Neurosci. Lett.2000:287:61-64.
[58]. Kaplan RE. Febrile seizures. When is treatment justified? Postgrad Med 1987;82:63-6,69-71.
[59]. Okubo T, Harada S. Polymorphism of the neuropeptide Y gene:an association study with alcohol withdrawal. Alcohol Clin Exp Res 2001;25:59S-62S.
[60]. Lin LC, Lin HS, Yang RC. Neuropeptide Y gene polymorphism and plasma neuropeptide Y level in febrile seizure patients in Taiwan. Kaohsiung J Med Sci.2007 Nov;23(11):560-5.
[61]. Dube C. Neuropeptide Y:potential role in recurrent developmental seizures. Peptides.2007 Feb;28(2):441-6. Epub 2006 Dec 29.
[62]. Mkemade A, Vuijst CL, Unmehopa UA, et al. Thyroid hormone receptor expression in the human hypothalamus and anterior pituitary. J Clin Endocrinol Metab.2005, 90:904-912.
[63]. Zhu XG, Robertson JT, Sacks HS, et al. Opioid and Tachykinin neuropeptides in prolactin-secretion human pituitary adenomas. Peptides,1995.16:1097-1107.
[64]. Grouzmann E, Deruaz JP, Gomes F, et al. Immunolocalization of neuropeptide Y in human potutary humours. [J] Regul Pept,1998,25:89-92.
[65]. Knerr I, Schuster S, Nomikos P, et al. Gene expression of adrenomedullin, leptin, their receptors and neuropeptide Y in hormone-secreting and non-functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans [J] Neuropathol Appl Neurobiol,2001,27(3):215-222.
[66]. Levy MJ, Classey JD, Maneesri S, et al. The relationship between neuropeptide Y expression and headache in pituitary tumours. Eur J Neurol.2006 Feb;13(2):125-9.
[67]. Larhammar D (1996) Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 62:1-11.
[2]. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke [J]. Stroke,2004,35: 212-227.
[3]. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes:a family history study [J]. Stroke,2003,34:1364-1369.
[4]. Lundberg JM, Terenius L, Hokfelt T, et al. Neuropeptide Y(NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function [J]. Acta Physiol Scand,1982,116:477-480.
[5]. Walker P, Grouzmann E, Burnier M, et al. The role of neuropeptide Y in cardiovascular regulation [J]. Trends Pharmacol Sci,1991,12:111-115.
[6]. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells:cooperation with noradrenaline and ATP [J]. Regul Pept,1994,50:259-265.
[7]. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium [J]. Circ Res, 1998,83:187-195.
[8]. Renner W, Grammer T, Hoffmann MM, et al. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population [J]. J Hypertens,2004,22:2398-2399.
[9]. Niskanen L, Karvonen MK, Valve R, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects [J]. J Clin Endocrinol Metab, 2000,85:2266-2269.
[10]. Michel MC, Rascher W. Neuropeptide Y:a possible role in hypertension? [J] J Hypertens,1995,13:385-395.
[11]. WHO Special Report. Stroke:recommendations on stroke prevention, diagnosis and therapy [J]. Stroke,1989,20:1407-1431.
[12]. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definition for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment [J]. Stroke,1993,24:35-41.
[13]. Excoffier, L., Laval, G., Schneider, S. Arlequin ver.3.0:an integrated software package for population genetics data analysis. Evol. Bioinform.2005.1, 47-50.
[14]. Jamrozik K, Broadhurst RJ, Anderson CS, et al. The role of lifestyle factors in the etiology of stroke. A population-based case-control study in Perth, Western Australia. Stroke 1994.25:51-9.
[15]. Alberts MJ. Genetics of cerebrovascular disease. Stroke.2004.35:342-344.
[16]. Bak S, Gaist D, Sindrup SH, et al. Genetic liability in stroke:a long-term follow-up study of Danish twins. Stroke.2002.33:769-774.
[17]. Jousilahti P, Rastenyte D, Tuomilehto J, et al. Parental history of cardiovascular disease and risk of stroke:a prospective follow-up of 14371 middle-aged men and women in Finland. Stroke.1997.28:1361-1366.
[18]. Woo D, Kaushal R, Kissela B, et al. Association of Phosphodiesterase 4D With Ischemic Stroke A Population-Based Case-Control Study. Stroke.2006.37:371-6.
[19]. Saleheen D, Bukhari S, Haider SR, et al. Association of Phosphodiesterase 4D Gene With Ischemic Stroke in a Pakistani Population. Stroke.2005.36:2270-7.
[20]. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet.2003.35:131-8.
[21]. Worrall BB, Brott TG, Brown RD Jr, et al. IL1RN VNTR Polymorphism in Ischemic Stroke Analysis in 3 Populations. Stroke.2007.38:1189-96.
[22]. Kim Y, Lee C. The Gene Encoding Transforming Growth Factor β 1Confers Risk of Ischemic Stroke and Vascular Dementia. Stroke.2006.37:2843-5.28.
[23]. Stanzione R., Di Angelantonio E., Evangelista A., et al. β 2-adrenergic receptor gene polymorphisms and risk of ischemic stroke. Am. J. Hypertens.2007.20, 657-662.
[24]. Heckbert S. R., Hindorff L. A., Edwards K. L., et al. Beta2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation. 2003.107,2021-2024.
[25]. Frikke-Schmidt R, Nordestgaard BG, Schnohr P, et al. A single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. A case-control and prospective study. Eur Heart J.2004.25: 943-951.
[26]. Howard TD, Giles WH, Xu J, et al. Promoter Polymorphisms in the Nitric Oxide Synthase 3 Gene Are Associated With Ischemic Stroke Susceptibility in Young Black Women. Stroke.2005.36(9):1848-51.
[27]. Hassan A, Gormley K,O'Sullivan M, et al. Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke.2004.35:654-659.34.
[28]. Voetsch B, Benke KS, Panhuysen CI, et al. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol.2004.61:351-356.
[29]. Slowik A, Dziedzic T, Turaj W, et al. A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke.2004.35:1589-1593.
[30]. Alberts MJ, Tournier-Lasserve E. Update on the genetics of stroke and cerebrovascular disease 2004. Stroke.2005.36:179-81.
[31]. Tatemoto K, Carlquist M, Mutt V. Neuropetide Y-a novel brain peptide with structural similarities to petide YY and pancreatic polypeptide. Nature.1982, 296:659-660.
[32]. Marklund U, Bystrom M, Gedda K, et al. Intron-mediated expression of the human neuropeptideY Y1 receptor. [J] Mol Cell Endocrinol.2002,188:85-97.
[33]. Mullins D, Kirby D, Hwa J, et al. Identification of potent and selective neuropeptide Y Y (1) receptor agonists with orexigenic activity in vivo. [J] Mol Pharmacol. 2001,60; 534-540.
[34]. Ishihara A, Kanatani A, Mashiko S, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain an d associated parameters in diet-induced obese mice. [J] PNAS.2006,103(18):7 154-7 158.
[35]. Pittner RA, Moore C X, Bhavsar S P, et al. Efects of PYY[3-36]in rodent models of diabetes and obesity. [J] Obes Relat Metab Disord.2004,28:963-971.
[36]. Ding B. Distribution of the NPY 1128C allele frequency in different populations [J]. J Neural Transm,2003,110:1199-1204.
[37]. Itokawa M, Arai M, Kato S, et al. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans [J]. Neurosci Lett,2003,347:202-204.
[38]. Shah SH, Freedman NJ, Zhang L, et al. Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis [J]. PLoS Genet,2009,5:e 1000318.
[39]. Allen G, Cheung R, Cechetto D. Neurochemical changes following occlusion of the middle cerebral artery in rats [J]. Neuroscience,1995,68:1037-1050.
[40]. Cheung RT, Diab T, Cechetto DF. Time-course of neuropeptide changes in peri-ischemic zone and amygdala following focal ischemia in rats [J]. J Comp Neurol, 1995,360:101-120.
[41]. Kharlamov EA, Kharlamov A, Kelly KM. Changes in neuropeptide Y protein expression following photothrombotic brain infarction and epileptogenesis [J]. Brain Res,2007,1127:151-162.
[42]. Chaeyoung Lee, Minyoung Kong. An Interactive Association of Common Sequence Variants in the Neuropeptide Y Gene With Susceptibility to Ischemic Stroke [J]. Stroke, 2007,38:2663-2669.
[43]. Minth C, Dixon J. Regulation of the human neuropeptide Y gene. Ann N Y Acad Sci.1990.611:99-110.
[44]. Bray MS, Boerwinkle E, Hanis CL. Sequence Variation within the Neuropeptide Y Gene and Obesity in Mexican Americans. Obes Res.2000.8(3):219-26.
[45]. Zill P, Preuss UW, Koller G, et al. Analysis of Single Nucleotide Polymorphisms and Haplotypes in the Neuropeptide Y Gene:No Evidence for Association With Alcoholism in a German Population Sample. Alcohol Clin Exp Res.2008.32(3):430-4.
[46]. Mottagui-Tabar S, Prince JA, Wahlestedt C, et al. A Novel Single Nucleotide Polymorphism of the Neuropeptide Y (NPY) Gene Associated With Alcohol Dependence. Alcohol Clin Exp Res.2005.29.(5):702-7.
[47]Buckland PR, Hoogendoorn B, Guy CA, et al. A high proportion of polymorphisms in the promoters of brain expressed genes influences transcriptional activity [J]. Biochim Biophys Acta,2004,1690:238-249.
[48]Kim NS, Oh SM, Ko MM, et al. Association of the C-399T promoter polymorphism of neuropeptide Y with susceptibility to ischemic stroke [J]. Clin Biochem,2009,42: 1699-1704.
[49]. Zhou Z, Zhu G, Hariri AR, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature.2008.24;452(7190):997-1001.
[1]. Lundberg JM, Terenius L, Hokfelt T, Martling CR, Tatemoto K, Mutt V, Polak J, BloomS, Goldstein M. Neuropeptide Y(NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982 Dec;116 (4):477-80.
[2]. Billington CJ, Briggs JE, Harker S, Grace M, Levine AS. Neuropeptide Y in hypothalamic paraventricular nucleus:a center coordinating energy metabolism. Am J Physiol.1994 Jun;266 (6 Pt 2):R1765-70.
[3]. Moltz JH, McDonald JK. Neuropeptide Y:direct and indirect action on insulin secretion in the rat. Peptides.1985 Nov-Dec;6 (6):1155-9.
[4]. Heilig M, McLeod S, Koob G.K and Britton K.T., Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41 (1992), pp.61-69.
[5]. C. J. Billington, J. E. Briggs, M. Grace and A. S. Levine, Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism, Am J Physiol 260 (1991), pp. R321-R327.
[6]. P.Walker, E. Grouzmann, M. Burnier and B. Waeber, The role of neuropeptide Y in cardiovascular regulation, Trends Pharmacol Sci 12 (1991), pp.111-115.
[7]. D. Erlinge, J. Brunkwall and L. Edvinsson, Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells:cooperation with noradrenaline and ATP, Regul Pept 50 (1994), pp.259-265.
[8]. Z. Zukowska-Grojec, E. Karwatowska-Prokopczuk, W. Rose, J. Rone, S. Movafagh, H. Ji, Y. Yeh, W. T. Chen, H. K. Kleinman, E. Grouzmann and D. S. Grant, Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium, Circ Res 83 (1998), pp.187-195.
[9]. Renner W, Grammer T, Hoffmann MM, Nauck MS, Winkelmann BR, Boehm BO, Marz W. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens.2004;22:2398-2399.
[10]. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm.2003;110:1199-1204.
[11]. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells:cooperation with noradrenaline and ATP. Regul Pept.1994;50:259-265.
[12]. Michel MC, Rascher W. Neuropeptide Y:a possible role in hypertension? J Hypertens.1995; 13:385-395.
[13]. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polak JM. Neuropeptide Y distribution in the rat brain. Science.1983;221:877-879.
[14].Dumont Y, Fournier A, St Pierre S, Quirion R. Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci.1993;13:73-86.
[15]. Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur. J Neurosci.1999;11:1431-1448.
[16]. Tu B, Timofeeva 0, Jiao Y, Nadler JV. Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain 1. J. Neurosci.2005;25:1718-1729.
[17]. Bidmon HJ, Emde B, Kowalski T, Schmitt M, Mayer B, Kato K, Asayama K, Witte OW, Zilles K. Nitric oxide synthase-I containing cortical interneurons co-express antioxidative enzymes and anti-apoptotic Bcl-2 following focal ischemia:evidence for direct and indirect mechanisms towards their resistance to neuropathology. J Chem Neuroanat.2001;22:167-184.
[18]. Kowianski P, Morys JM, Wojcik S, Dziewiatkowski J, Luczynska A, Spodnik E, Timmermans JP, Morys J. Neuropeptide-containing neurons in the endopiriform region of the rat:morphology and colocalization with calcium-binding proteins and nitric oxide synthase. Brain Res.2004; 996:97-110.
[19]. Tatemoto K, Carlquist M, Mutt V. Neuropetide Y-a novel brain peptide with structural similarities to petide YY and pancreatic polypeptide. Nature.1982, 296:659-660.
[20]. Marklund U, Bystrom M, Gedda K, et al. Intron-mediated expression of the human neuropeptideY Y1 receptor. [J] Mol Cell Endocrinol.2002,188:85-97.
[21]. Mullins D, Kirby D, Hwa J, et al. Identification of potent and selective neuropeptide Y Y(1)receptor agonists with orexigenic activity in vivo. [J] Mol Pharmacol. 2001,60; 534-540.
[22]. Ishihara A, Kanatani A, Mashiko S, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain an d associated parameters in diet-induced obese mice. [J] PNAS.2006,103(18):7 154-7 158.
[23]. Pittner RA, Moore C X, Bhavsar S P, et al. Efects of PYY[3-36]in rodent models of diabetes and obesity. [J] Obes Relat Metab Disord.2004,28:963-971.
[24]. Markus HS, Alberts MJ. Update on genetics of stroke and cerebrovascular disease. Stroke.2006; 37:288-290.
[25]. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes:a family history study. Stroke.2003; 34: 1364-1369.
[26]. Kim Y, Lee C. The gene encoding transforming growth factor β1 confers risk of ischemic stroke and vascular dementia. Stroke.2006; 37:2843-2845.
[27]. Dichgans M, Markus HS. Genetic association studies in stroke:methodological issues and proposed standard criteria. Stroke.2005; 36:2027-2031.
[28]. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature.2001; 410:940-944.
[29]. Michel MC, Rascher W. Neuropeptide Y:a possible role in hypertension? J Hypertens.1995; 13:385-395.
[30]. Renner W, Grammer T, Hoffmann MM, Nauck MS, Winkelmann BR, Boehm BO, Marz W. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population.J Hypertens.2004; 22:2398-2399.
[31]. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm.2003; 110:1199-1204.
[32]. Allen GV, Cheung RT, Cechetto DF. Neurochemical changes following occlusion of the middle cerebral artery in rats. Neuroscience.1995;68:1037-1050.
[33]. Cheung RT, Diab T, Cechetto DF. Time-course of neuropeptide changes in peri-ischemic zone and amygdala following focal ischemia in rats. J Comp Neurol. 1995;360:101-120.
[34]. Grimaldi R, Zoli M, Agnati LF, Ferraguti F, Fuxe K, Toffano G, Zini I. Effects of transient forebrain ischemia on peptidergic neurons and astroglial cells:evidence for recovery of peptide immunoreactivities in neocortex and striatum but not hippocampal formation. Exp. Brain Res.1990;82:123-136.
[35]. Kharlamov EA, Kharlamov A, Kelly KM. Changes in neuropeptide Y protein expression following photothrombotic brain infarction and epileptogenesis. Brain Res. 2007 Jan 5;1127 (1):151-62.
[36]. Chaeyoung Lee, PhD Minyoung Kong, MS. An Interactive Association of Common Sequence Variants in the Neuropeptide Y Gene With Susceptibility to Ischemic Stroke. Stroke.2007 Oct;38 (10):2663-9.
[37]. De Quidt ME, Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system:Ⅱ. Immunohistochemical analysis. Neuroscience 1986;18:545-618.
[38]. Woldbye DP, Larsen PJ, Mikkelsen JD, et al. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat Med 1997:3:761-4.
[39]. Dube C, Brunson KL, Eghbal-Ahmadi M, et al. Endogenous neuropeptide Y prevents recurrence of experimental febrile seizures by increasing seizure threshold. J Mol Neurosci 2005:25:275-83.
[40]. Marsh DJ, Baraban SC, Hollopeter G, et al. Role of the Y5 neuropeptide Y receptor in limbic seizures. Proc Natl Acad Sci USA 1999:96:13518-23.
[41]. Erickson JC, Klegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996;381:415-21.
[42]. Baraban SC, Hollopeter G, Erickson JC, Schwartzkroin PA, Palmiter RD. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci. 1997;17:8927-8936.
[43]. Woldbye, DP; Madsen, TM; Larsen, PJ; Mikkelsen, JD; Bolwig, TG. Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Res.1996;737:162-8.
[44]. Hollrigel, GS; Chen, K; Baram, TZ; Soltesz, I. The pro-convulsant actions of corticotropin-releasing hormone in the hippocampus of infant rats. Neuroscience. 1998;84:71-9.
[45]. Tu, B; Timofeeva,O; Jiao, Y; Nadler, JV. Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain. J Neurosci.2005:25:1718-29.
[46]. Vezzani, A; Sperk, G; Colmers, WF. Neuropeptide Y:emerging evidence for a functional role in seizure modulation. Trends Neurosci.1999;22:25-30.
[47]. Kelly KM, Kharlamov A, Hentosz TM, Kharlamova EA, Williamson JM, Bertram EH III, Kapur J, Armstrong DM. Photothrombotic brain infarction results in seizure activity in aging Fischer 344 and Sprague Dawley rats. Epilepsy Res.2001:47:189-203.
[48]. Kharlamov EA, Jukkola PI, Schmitt KL, Kelly KM. Electrobehavioral characteristics of epileptic rats following photothrombotic brain infarction. Epilepsy Res.2003:56:185-203. [49]. Causing CG, Makus KD, Ma Y, Miller FD, Colmers WF. Selective upregulation of T alpha 1 alpha-tubulin and neuropeptide Y mRNAs after intermittent excitatory stimulation in adult rat hippocampus in vivo. J Comp Neurol.1996;367:132-146.
[50]. Gruber B, Greber S, Rupp E, Sperk G. Differential NPY mRNA expression in granule cells and interneurons of the rat dentate gyrus after kainic acid injection. Hippocampus.1994;4:474-482.
[51]. Marksteiner J, Ortler M, Bellmann R, Sperk G. Neuropeptide Y biosynthesis is markedly induced in mossy fibers during temporal lobe epilepsy of the rat. Neurosci. Lett.1990;112:143-148.
[52]. Marksteiner J, Sperk G. Concomitant increase of somatostatin, neuropeptide Y and glutamate decarboxylase in the frontal cortex of rats with decreased seizure threshold. Neuroscience.1988;26:379-385. [PubMed]
[53]. Marksteiner J, Sperk G, Maas D. Differential increases in brain levels of neuropeptide Y and vasoactive intestinal polypeptide after kainic acid-induced seizures in the rat. Naunyn Schmiedebergs Arch. Pharmacol.1989:339:173-177.
[54]. McCarthy JB, Walker M, Pierce J, Camp P, White JD. Biosynthesis and metabolism of native and oxidized neuropeptide Y in the hippocampal mossy fiber system. J Neurochem. 1998;70:1950-1963.
[55]. Tu B, Timofeeva 0, Jiao Y, Nadler JV. Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain 1. J. Neurosci.2005;25:1718-1729.
[56]. Colmers WF, El Bahh B. Neuropeptide Y and Epilepsy. Epilepsy Curr. 2003;3:53-58.
[57]. DePrato Primeaux S, Holmes PV, Martin RJ, Dean RG, Edwards GL. Experimentally induced attenuation of neuropeptide-Y gene expression in transgenic mice increases mortality rate following seizures. Neurosci. Lett.2000:287:61-64.
[58]. Kaplan RE. Febrile seizures. When is treatment justified? Postgrad Med 1987;82:63-6,69-71.
[59]. Okubo T, Harada S. Polymorphism of the neuropeptide Y gene:an association study with alcohol withdrawal. Alcohol Clin Exp Res 2001;25:59S-62S.
[60]. Lin LC, Lin HS, Yang RC. Neuropeptide Y gene polymorphism and plasma neuropeptide Y level in febrile seizure patients in Taiwan. Kaohsiung J Med Sci.2007 Nov;23(11):560-5.
[61]. Dube C. Neuropeptide Y:potential role in recurrent developmental seizures. Peptides.2007 Feb;28(2):441-6. Epub 2006 Dec 29.
[62]. Mkemade A, Vuijst CL, Unmehopa UA, et al. Thyroid hormone receptor expression in the human hypothalamus and anterior pituitary. J Clin Endocrinol Metab.2005, 90:904-912.
[63]. Zhu XG, Robertson JT, Sacks HS, et al. Opioid and Tachykinin neuropeptides in prolactin-secretion human pituitary adenomas. Peptides,1995.16:1097-1107.
[64]. Grouzmann E, Deruaz JP, Gomes F, et al. Immunolocalization of neuropeptide Y in human potutary humours. [J] Regul Pept,1998,25:89-92.
[65]. Knerr I, Schuster S, Nomikos P, et al. Gene expression of adrenomedullin, leptin, their receptors and neuropeptide Y in hormone-secreting and non-functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans [J] Neuropathol Appl Neurobiol,2001,27(3):215-222.
[66]. Levy MJ, Classey JD, Maneesri S, et al. The relationship between neuropeptide Y expression and headache in pituitary tumours. Eur J Neurol.2006 Feb;13(2):125-9.
[67]. Larhammar D (1996) Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 62:1-11.